By Tanae Howard
INDIANAPOLIS - New technology being developed by researchers at the University of Bradford in the United Kingdom could be the future of early cancer diagnosis.
It’s called the lymphocyte genome sensitivity test. Researchers tested a couple hundred patients with cancer and those who were healthy. They looked at white blood cells under a UVA light. They found those with cancer had more damaged DNA than those who were healthy.
We spoke to a local oncologist who says this could be a medical breakthrough for early detection but there’s still more work to be done.
"Those with higher probability you can reach cancer diagnosis early and start treatment early and hopefully get better outcomes. And those with low probability of cancer you can avoid a lot of anxiety a lot of unnecessary test and can get some peace of mind to the patients and parents," said St. Vincent Child Oncologist, Dr. Bassem Razzouk.
The initial study involved patients with melanoma, lung cancer and colon cancer. Now the test will be performed on a wider range of subjects and different types of cancers.
Dr. Razzouk says the testing would also have to be validated. He projects it’s at least more than two years away from being on the market.